Meta AnalysisID 328
含甘草的中药复方治疗COVID-19的疗效：Meta分析与系统评价
CRD42022322821
Do prescriptions containing licorice root in the treatment of COVID-19 have obvious advantages over traditional treatments? In what ways are they reflected? How do licorice-containing Chinese medicine prescriptions diffe
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Herb: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 328
- Evidence Id
- 8886
- Core Evidence Id
- 8886
- Source Meta Analysis Id
- 308
- Herb2 Meta Analysis Id
- HBMA000308
- Crd Id
- CRD42022322821
- Title
- Efficacy of Chinese herbal prescriptions containing licorice in the treatment of COVID-19: meta-analysis and systematic review
- Review Question
- Do prescriptions containing licorice root in the treatment of COVID-19 have obvious advantages over traditional treatments? In what ways are they reflected? How do licorice-containing Chinese medicine prescriptions differ in the treatment of COVID-19? From recent research, what are the main advantages of prescription licorice-containing herbal medicines for the treatment of COVID-19? Can licorice-containing herbal prescription interventions prevent, treat or improve outcomes in social emergencies such as the COVID-19 pandemic?
- Study Type Included
- We selected all the RCTs for meta-analysis. Quasi-RCTs, non-RCTs, and randomized trials with false randomization methods were excluded.
- Condition Being Studied
- Herbal medicines combined with traditional conventional therapies have achieved great success in the treatment of COVID-19. During this COVID-19 outbreak, more than 90% of confirmed COVID-19 patients in China were treated with herbal medicine combined with traditional conventional therapies (State Council Information Office Press Conference, 2020).
- Participant
- Inclusion: patients with 2019 novel coronavirus pneumonia (according to the international diagnostic criteria for novel coronavirus pneumonia). Excluded: undiagnosed or suspected COVID-19 patients.
- Animal
- Human Disease Modelled
- Intervention
- Includes prescription treatments centered on licorice, combined with traditional remedies. The quantity of other traditional Chinese medicines contained in the formula is not limited, and the administration method, dosage or course of treatment is not limited. The control group received traditional therapy alone.
- Comparator Control
- Purely using traditional Western medicine treatment plan.
- Main Outcome
- Rate of disease progression (proportion of patients who have progressed from mild or ordinary types to severe or critical types after treatment), negative conversion rate of nucleic acid (proportion of patients whose nucleic acid test become negative after treatment), and improvement rate of chest CT (number of patients whose CT lesions disappeared or decreased after treatment as a percentage of all patients treated).
- Outcome Measure
- Additional Outcome
- Total effective rate (number of patients cured plus the number in remission per group divided by the total number of patients in each group), incidence of adverse events (number of patients with side effects after treatment as a percentage of all patients treated), disappearance rate of main symptoms (number of patients whose symptoms [fever, cough, and fatigue] disappeared after treatment as a percentage of all patients treated), lymphocyte count, and length of hospital stay.
- Study Method
- Intervention, Meta-analysis, Systematic review
- Keyword
- COVID-19; Drugs, Chinese Herbal; Glycyrrhiza; Humans; Medicine, Chinese Traditional; Prescriptions; SARS-CoV-2; Treatment Outcome
- Contact
- Zecheng Li [email protected]
- Organisational Affiliation
- China-Japan Friendship Hospital
- Funding Source
- The National Natural Science Foundation of China Grant number(s) <span style=font-size: 14px>State the funder, grant or award number and the date of award</span> No. 81641191
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-04-02
- Registration Date
- 2022-04-04
- Anticipated Start Date
- 2022-04-10
- Anticipated Completion Date
- 2022-05-20
- Title Cn
- 含甘草的中药复方治疗COVID-19的疗效：Meta分析与系统评价
- Title En
- Efficacy of Chinese herbal prescriptions containing licorice in the treatment of COVID-19: meta-analysis and systematic review
- Bilingual Status
- complete